Biosimilars & Follow-on Biologics Americas 2018 Biosimilars and Follow-on Biologics 2018 Americas

Biosimilars and Follow-on Biologics 2018 Americas will be started on 19 Apr and it will be ended on 20 Apr 2018.

Biosimilars & Follow-on Biologics Americas 2018 will be in Washington, D.C., Washington USA but the venue of the event is not determined yet.

Biosimilars & Follow-on Biologics Americas 2018, Biosimilars and Follow-on Biologics 2018 Americas is going to be about Pharmaceutical, Biotechnology, Therapeutics, Biosimilars and Biologics.

Biosimilars and Follow-on Biologics 2018 Americas is an annual Conference.

The professional congress organizer of the Biosimilars & Follow-on Biologics Americas 2018, Biosimilars and Follow-on Biologics 2018 Americas is Paradigm Global Events.

When you are in Washington, D.C. for Biosimilars & Follow-on Biologics Americas 2018, uncover these three must visit parts and adore the enchantment of this city:

• Must do in Washington, D.C.
• Must visit in Washington, D.C.
• Must taste in Washington, D.C.

The increasing pressure to decrease healthcare expenditures, growing demand due to its cost-effectiveness, expanding occurrence of different diseases, increasing numbers of biologics losing their market exclusivity, positive outcomes in ongoing clinical trials and rising demand in various therapeutic applications are all contributing factors for growth of the biosimilars market. Between 2015 and the end of 2019, 39 biologics with combined US sales of $41 billion, representing 30% of the total market will lose their marketing exclusivity. This resulted in huge interest by big pharma and biotech company venturing into the Biosimilar sector in order to gain a slice of multibillion worth of biologics market. Other factors increasing the demand for biosimilar drugs include rising disease incidences across the globe and better access to healthcare for all nations. Circumstance such as high manufacturing complexities and costs, rigorous regulatory requirements in countries, and innovative strategies by biologic drug manufacturers to restrict the entry of new players are restraining the growth of this market. In this congress, we will cover a diverse range of topic and address the challenges and obstacle encountered by the industry from development to successful market of biosimilars. This will also offer and provide a unique platform for knowledge sharing and convergence from Pharmaceuticals, Biotechnology, Regulatory and many more.